Central Nervous System
FDA greenlights Neuralink for human trials
The US Food and Drug Administration (FDA) has approved Neuralink for its first in-human study. In a Twitter announcement, the…
BIAL R&D doses first patient in ACTIVATE study of BIA 28-6156
BIAL R&D has dosed the first patient in its Phase II ACTIVATE study of BIA 28-6156 to treat patients with…
Cybin doses first healthy volunteers in Part C of CYB004 study
Cybin has dosed the first healthy volunteers in the ongoing Part C of Phase I study of CYB004 to treat…
First subjects in IBC’s Phase Ib trial receive IBC-Ab002
ImmunoBrain Checkpoint (IBC) has announced the dosing of the first two patients in a Phase Ib trial of IBC-Ab002 to…
First patient dosed in Inhibikase’s Phase II Parkinson’s disease trial
Inhibikase Therapeutics has dosed the first patient in a Phase II ‘201’ clinical trial of IkT-148009 for the treatment of…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Roche’s BTK inhibitor succeeds in a Phase II MS trial
Roche’s fenebrutinib achieved positive results in a Phase II clinical trial in patients with relapsing forms of multiple sclerosis (RMS),…
Coya Therapeutics reports positive data from small Alzheimer’s disease trial
Coya Therapeutics has announced positive data from a small trial in Alzheimer’s disease as the company looks to build out…
Pipeline Moves: Hengrui Medicine Phase III breast cancer termination lowers approval prospects
This week on Pipeline Moves, we start by investigating terminations of a Phase III trial in breast cancer, a Phase…
NeuroSense makes key progress in Phase II ALS trial
NeuroSense Therapeutics has completed enrolment of a Phase IIb trial in amyotrophic lateral sclerosis (ALS), marking an important milestone in…
Larimar reports results from Friedreich’s ataxia drug trial
US-based biotechnology company Larimar Therapeutics has reported preliminary top-line results from a trial of CTI-1601 for the treatment of Friedreich’s…